MBII Marrone Bio Innovations Inc

Marrone Bio Innovations Product Venerate XC Bioinsecticide Now Available in California

Today, Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced the availability of Venerate XC bioinsecticide in California. Venerate XC is a liquid microbial-based, contact and ingestion insecticide that degrades insect exoskeletons and interferes with molting of chewing insects, nymphs and adult sucking insects, as well as with flies and mites. Available in California in 2015, Venerate is labeled for use at 4 to 8 quarts per acre. With the recent California Department of Pesticide Regulation approval, Venerate XC is labeled at a lower rate of 1 to 4 quarts per acre.

Tony Torres, MBI’s Insecticide and Nematicide Product Manager, said, “We are pleased that California growers now have access to this formulation. This is an important product for California because it allows growers to use Venerate XC at a lower rate, providing more economically efficient pest management.”

Venerate XC is approved for use on a wide variety of California’s fruit, vegetable, vine and nut crops in conventional integrated pest management (IPM) and organic systems. It is an easy-handling liquid formulation with flexibility to apply by ground or air. There is no limit to the number of applications allowed per season, (unlike many chemical products that have high risk for pest resistance development), and Venerate XC has a minimal four hour re-entry interval (REI). The product is non-toxic to fish, birds, and most beneficial insects including honeybees, and also has the advantage of a zero-day pre-harvest interval (PHI) and an exemption from MRL (maximum residue level) tolerances—a measure of pesticide residue limits that must be met for most food crop exports.

With a unique mode of action, Venerate XC is an effective addition to a conventional IPM program. When used along with MBI’s other bioinsecticide, Grandevo, which is also a broad-spectrum insecticide, farmers have two bioinsecticides to help with resistance and residue management. When used in an IPM program, Grandevo is best used early to help suppress insect populations. Venerate XC should be used first if adult insects or mites are present. MBI’s biological insecticides are not intended for use as rescue treatments, but rather are preventative, meaning they are most effective when used before target populations are at a critical threshold.

All MBI products should be used in accordance with label directions.

About Marrone Bio Innovations

Smart. Natural. Solutions.

Marrone Bio Innovations, Inc. (NASDAQ: MBII) aims to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have four products for agriculture on the market--Regalia®, Grandevo®, Venerate® and Majestene®- and also distribute Bio-tam® 2.0 for Isagro USA. MBI also markets Zequanox® for invasive mussels, a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.

Regalia, Venerate, Grandevo and Majestene are registered trademarks of Marrone Bio Innovations. Bio-Tam 2.0 is a registered trademark of Isagro U.S.A.

EN
26/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Marrone Bio Innovations Inc

 PRESS RELEASE

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement wi...

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp. RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI’s stockholde...

 PRESS RELEASE

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Res...

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the ...

 PRESS RELEASE

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednes...

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednesday, May 11 at 4:30 p.m. Eastern Time RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations’ first quarter financial re...

 PRESS RELEASE

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 202...

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was ...

 PRESS RELEASE

Marrone Bio Expands Biological Seed Treatment Collaboration for Row Cr...

Marrone Bio Expands Biological Seed Treatment Collaboration for Row Crops Company poised for continued growth in a $6+ billion market¹ RALEIGH, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), has signed an agreement with Corteva Agriscience (NYSE: CTVA) that expands the opportunity for MBI technologies to be used on seeds sold by Corteva for row crops globally. Marrone Bio currently provides seed treatment solutions to Corteva for use throughout Europe. MBI introduced biological seed treatments as a sustainable alternative to control yield-robbing pests in the United States i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch